Kara Patrick

发表

Genomic Effects of IFN-β in Multiple Sclerosis Patients 1

Murali Ramanathan, Joan Feichter, Bianca Weinstock-Guttman, 2003, The Journal of Immunology.

Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis

Robert Zivadinov, Murali Ramanathan, Nadir Abdelrahman, 2007, Journal of Neuroimmunology.

Risk of bone loss in men with multiple sclerosis

M. Ramanathan, Colleen M. Miller, B. Weinstock-Guttman, 2004, Multiple sclerosis.

Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients

M. Ramanathan, B. Weinstock-Guttman, M. Baier, 2006 .

In vivo gene expression revealed by cDNA arrays: the pattern in relapsing–remitting multiple sclerosis patients compared with normal subjects

M. Ramanathan, Colleen M. Miller, L. Jacobs, 2001, Journal of Neuroimmunology.

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis

M. Benatar, M. Bromberg, M. Pasnoor, 2020, JAMA neurology.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

M. Ramanathan, R. Bakshi, F. Munschauer, 2008, Journal of Neuroimmunology.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Dynamics of immune cell trafficking in interferon-β treated multiple sclerosis patients

M. Ramanathan, B. Weinstock-Guttman, M. Baier, 2003, Journal of Neuroimmunology.

Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study

R. Benedict, B. Weinstock-Guttman, D. Cookfair, 2013, Journal of Neurology.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.

Dalfampridine benefits ambulation but not cognition in multiple sclerosis

R. Motl, R. Benedict, B. Weinstock-Guttman, 2020, Multiple sclerosis.

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation

D. Ramasamy, R. Zivadinov, B. Weinstock-Guttman, 2016, Journal of Neurology, Neurosurgery & Psychiatry.

Genomic effects of IFN-beta in multiple sclerosis patients.

Murali Ramanathan, Joan Feichter, Bianca Weinstock-Guttman, 2003, Journal of immunology.

Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients.

M. Ramanathan, B. Weinstock-Guttman, M. Baier, 2006, Multiple sclerosis.